论文部分内容阅读
目的探讨类胚胎致死性异常视觉基因1(ELAV1)在卵巢浆液性肿瘤组织中的表达与卵巢浆液性癌化疗耐药及预后的关系。方法采用免疫组化法对2010年1月至2013年2月中国医科大学附属盛京医院收治的40例卵巢浆液性癌(化疗耐药20例和化疗敏感20例)、15例卵巢交界性浆液性瘤、20例卵巢良性浆液性瘤及15例正常卵巢组织中的ELAV1蛋白表达进行检测,并对ELAV1表达与患者临床病理资料及生存率的关系进行分析。结果 (1)ELAV1蛋白胞浆在卵巢浆液性癌中的阳性表达率明显高于卵巢交界性浆液性瘤、卵巢良性浆液性瘤和正常卵巢组织(P<0.05),且在卵巢癌化疗耐药组织中明显高于化疗敏感组织(P<0.05)。(2)ELAV1蛋白胞核阳性表达率在卵巢浆液性癌、卵巢交界性浆液性瘤、卵巢良性浆液性瘤及正常卵巢组织中差异无统计学意义(P>0.05)。(3)胞浆ELAV1的表达与卵巢浆液性癌FIGO病理分期及淋巴结转移情况相关(P<0.05),与患者年龄、是否绝经及分化程度无关(P>0.05)。(4)Kaplan-Meier生存分析提示:ELAV1蛋白胞浆阳性和化疗耐药患者生存时间短。结论 ELAV1可能与卵巢浆液性癌的发生发展相关,可作为预测卵巢浆液性癌化疗耐药及预后的指标。
Objective To investigate the relationship between the expression of embryonic lethal abnormal visual gene 1 (ELAV1) in ovarian serous tumors and the drug resistance and prognosis of ovarian serous carcinoma. Methods 40 cases of ovarian serous carcinoma (20 cases of chemoresistance and 20 cases of chemotherapy) were treated with Shengjing Hospital affiliated to China Medical University from January 2010 to February 2013 by immunohistochemistry. Fifteen cases of borderline serous 20 cases of benign ovarian serous tumors and 15 cases of normal ovarian tissue were detected by ELISA. The relationship between ELAV1 expression and clinicopathological data and survival rate was analyzed. Results (1) The positive expression rate of cytoplasm of ELAV1 protein in ovarian serous carcinoma was significantly higher than that in borderline serous ovarian tumor, benign serous ovarian tumor and normal ovarian tissue (P <0.05) Tissue was significantly higher than chemotherapy-sensitive tissues (P <0.05). (2) There was no significant difference in the positive expression rate of ELAV1 protein in ovarian serous carcinoma, borderline serous ovarian tumor, benign serous ovarian tumor and normal ovarian tissue (P> 0.05). (3) The expression of cytoplasmic ELAV1 was correlated with FIGO pathological stage and lymph node metastasis in ovarian serous carcinoma (P <0.05), but not with age, clinical stage of menopause and differentiation (P> 0.05). (4) Kaplan-Meier survival analysis suggested that ELAV1 protein cytoplasmic and chemoresistant patients had short survival time. Conclusion ELAV1 may be related to the occurrence and development of ovarian serous carcinoma and may be used as an index to predict the drug resistance and prognosis of ovarian serous carcinoma.